Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 10

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 10
---
 stock, par value $0.0001 per share, of which no shares are issued and outstanding as of December 31, 2024, in one or more series. Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in one or more series and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of our preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of our preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-upof our Company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. The issuance of preferred stock with voting and conversion rights could adversely affect the voting power of holders of common stock and reduce the likelihood that holders of shares of our common stock will receive dividend payments and payments upon liquidation. If we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the Commission. To the extent required, this description will include:

| • |     | the title and stated value; |

| • |     | the number of shares offered, the liquidation preference per share and the purchase price; |

| • |     | the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; |

| • |     | whether dividends will be cumulative or non-cumulative and, if 
 cumulative, the date from which dividends will accumulate;     |

| • |     | the procedures for any auction and remarketing, if any; |

| • |     | the provisions for a sinking fund, if any; |

| • |     | the provisions for redemption, if applicable; |

| • |     | any listing of the preferred stock on any securities exchange or market; |

| • |     | whether the preferred stock will be convertible into our common stock,